The pancreatic-cancer vaccine follow-up adds evidence of persistent immune responses and longer observation of the original Phase 1 cohort. It does not supply a randomized vaccine-versus-no-vaccine comparison. The 2025 paper and the April 2026 conference account should be read as related follow-up, not two independent replications. 1 2
The candidate is autogene cevumeran, an individualized RNA neoantigen vaccine studied in a treatment sequence that also included surgery, atezolizumab and chemotherapy. The original 2023 report explains that sequence. 3
What the 2025 paper added
The Nature paper, published February 19, 2025, reported a median follow-up of 3.2 years. The eight immune responders had longer recurrence-free survival than the eight nonresponders; the reported median was not reached in responders versus 13.4 months in nonresponders. It also described persistent functional vaccine-induced CD8 T-cell clones. 1
Our current access was the complete abstract in an author-affiliated institutional repository. The detailed paper and supplement were not reliably accessible in this pass. That distinction limits how deeply this report can assess the immune-tracking methods.
The biological finding and the clinical association belong in separate sentences. Persistence of the intended cells helps establish durability of the immune response. It is not itself a randomized estimate of how much the vaccine improved survival.
What the 2026 conference account said
On April 21, 2026, MSK summarized additional follow-up: seven of eight immune responders were alive, compared with two of eight nonresponders. It reported a median follow-up of 4.2 years, while also describing the work in a six-year time frame. 2
The source was the institution’s account of conference findings. The linked conference abstract and a corresponding full 2026 paper were not inspected here. The institution participated in the work; its account should be attributed, not presented as independent validation.
Why “87.5% survival” needs qualification
Seven divided by eight is 87.5%. The arithmetic is straightforward; the interpretation is not.
The denominator is the subgroup with the defined immune response, not every vaccinated participant or every person with pancreatic cancer. The groups were not randomized to have or lack that response. A median observation period also does not mean every person was followed for exactly that duration.
It would therefore be incorrect to turn the account into “the vaccine gives pancreatic-cancer patients an 87.5% six-year survival rate.” That sentence changes the population, changes an observed subgroup into a causal treatment promise, and imposes a uniform observation time the account does not provide. 2
The defensible conclusion is narrower: the institutional report describes a favorable long-term association in a small immune-responder group.
Keep three clocks and two endpoints separate
| Distinction | Why it changes the meaning |
|---|---|
| Publication date | When a paper or account appeared, not when everyone started treatment |
| Data follow-up | How long participants had been observed at that analysis |
| Program history | Time since the research began, not necessarily each participant’s follow-up |
| Recurrence-free survival | A disease-recurrence/death endpoint, with its specified definition |
| Overall survival | Whether participants remain alive, regardless of whether recurrence occurred |
A person can experience recurrence and still be alive. Reporting one endpoint as though it were the other changes the clinical claim. The earlier paper and later conference account discuss different aspects of follow-up; they are not interchangeable result labels. 1 2
What remains to be learned
The association is consistent with the idea that a productive vaccine-induced immune response may matter clinically. The small responder comparison cannot determine the vaccine’s incremental benefit independently of the surrounding treatment sequence and participant differences.
A controlled study is the appropriate next kind of evidence for that incremental-benefit question. MSK described a multicenter Phase 2 effort in its account, but this page does not claim current site recruitment or eligibility. 2
For context on how a randomized vaccine combination is reported, compare the melanoma trial history, without comparing their outcome percentages as though they involved equivalent diseases and participants.
Availability and the next update
None of these cited follow-up reports establishes a routine commercial price, general availability or a cure. They are not reasons to discontinue recommended care or to purchase unverified treatment access.
This record should change when a clearly identified new analysis, controlled result or regulatory event occurs—not simply because another outlet repeats the responder percentage. The cancer-vaccine guide keeps this program separate from other vaccines, and the trial-access explanation identifies official search routes without promising enrollment.